Cardiovascular Outcomes in Systemic Lupus Erythematosus (Jan, 10.1007/s11886-021-01626-9, 2022)

被引:0
作者
Sairam, Shrilekha [1 ]
Sureen, Amit [2 ]
Gutierrez, Jesus [2 ]
Dang, The Q. [2 ]
Mishra, Kunal [2 ]
机构
[1] Univ Texas El Paso, Hlth Sci Ctr, Div Rheumatol, Dept Internal Med,Paul L Foster Sch Med, El Paso, TX 79968 USA
[2] Texas Tech Univ, Hlth Sci Ctr, Dept Internal Med, Paul L Foster Sch Med, 4800 Alberta Ave, El Paso, TX 79905 USA
关键词
Antiphospholipid antibodies; Cardiac manifestation; Cardiovascular risk factors; Primary prevention; Risk stratification; Systemic lupus erythematosus;
D O I
10.1007/s11886-022-01665-w
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose of the Review: To review cardiovascular outcomes (CVE) in systemic lupus erythematosus (SLE) that evolves over time. Recent Findings: Inception cohorts now report long-term data, and large population registries add to our knowledge. Mortality and cardiovascular morbidity remain high with a risk ratio of 2–3. SLE disease activity–related inflammation accounts for higher CVE incidence ratio in the first year following diagnosis with accelerated atherosclerosis contributing to CVE in about a quarter to a third of the patients later in the disease course. Immunomodulation and disease control are associated with improved cardiovascular outcomes. Validation of modified risk stratification tools and studies evaluating primary prevention with aspirin and hydroxychloroquine are reported. Summary: Increased awareness of high mortality associated with cardiac inflammation, improved outcomes with early disease control, aggressive management of risk factors, hypertension, obesity, and high cholesterol with modifying risk stratification will result in more favorable outcomes in SLE patients. © 2022, This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.
引用
收藏
页码:85 / 85
页数:1
相关论文
共 1 条
  • [1] Sairam S, 2022, CURR CARDIOL REP, V24, P75, DOI 10.1007/s11886-021-01626-9